Potent, cell-permeable, ATP-competitive inhibitor of Pim-1/2 kinases (IC50 = 150 nM and 20 nM against Pim-1 and Pim-2, respectively) as well as DYRK1alpha (68% inhibition of DYRK1alpha and Pim-2 at 5 µM), while exhibiting little or no activity against a panel of 57 other kinases (<18% inhibition at 5 µM). Reported to exhibit antitumor activity in PC3 human prostate cancer cultures in vitro (IC50 = 48 µM) and in JC adenocarcinoma-transplanted Balb/C mice in vivo (~46% tumor mass reduction on day 20| 50 mg/kg via daily i.p.).